Moffitt Presentations at AACR 2023

Friday, April 14

Time	Room	Type	Abstract No.	Abstract Title	Authors
4-4:20 p.m.	Tangerine Ballroom 3-4 (WF3-4)	Educational Session		Tumor Cell Adaptability and Stress Response	Gina M. DeNicola

Saturday, April 15

Time	Room	Type	Abstract No.	Abstract Title	Authors
8-8:20 a.m.	Tangerine Ballroom 3-4 (WF3-4)	Educational Session (presenter and session chair)		Competing for attention: Myeloid and T cell spatial interactions	Brian Ruffell
10:30-10:50 a.m.	Valencia A	Educational Session		Epigenetic control of dormancy	Ana P. Da Silva Gomes
12:30-2 p.m.	Room W315	Major Symposium		Making Your Voices Heard: AACR's Advocacy Efforts with Policy Makers-Dedicated to the Memory of Chairman John Edward Porter	John DeMuro

Sunday, April 16

Time	Room	Type	Abstract No.	Abstract Title	Authors
1:30-1:50 p.m.	Room W414	Major Symposium		Metabolic reprogramming: a bridge between aging and tumor progression	Ana P. Da Silva Gomes
1:30-5 p.m.	Poster Hall / Section 31	Poster Session	847 / 5	Applying the principles of convexity and concavity to guide treatment scheduling of ALK inhibitors in non-small cell lung cancer	Jeffrey West
1:30-5 p.m.	Poster Hall / Section 31	Poster Session	852 / 10	Predicting progression in metastatic castrate-sensitive prostate cancer by coupling PSA and testosterone dynamics to a mechanistic mathematical model	Jill Gallaher
1:30-5 p.m.	Poster Hall / Section 31	Poster Session	853/11	The impact of normal tissue density on tumor growth and evolution in a 3D whole-tumor model of lung cancer	Rafael Ramon Bravo
1:30-5 p.m.	Poster Hall / Section 39	Poster Session	962 / 13	Oncodrivers expression analysis in primary tumors: potential for development of targeted immunotherapies for triple negative breast cancer (TNBC)	Saurabh K. Garg
1:30-5 p.m.	Poster Hall / Section 40	Poster Session	987 / 5	Seamless statistical analysis of adverse event data for clinical association	Dung-Tsa Chen
1:30-5 p.m.	Poster Hall / Section 37	Poster Session	887 / 2	Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint modulates CAR-T cell effector function	Miguel Gomez Fontela
1:30-5 p.m.	Poster Hall / Section 38	Poster Session	943 / 23	Informatics-based and other approaches to estimate real world disease progression in lung cancer	Rossybelle P. Amorrortu
1:30-5 p.m.	Poster Hall / Section 19	Poster Session	552 / 19	Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC	Bina Desai
1:30-5 p.m.	Poster Hall / Section 16	Poster Session	452 / 16	Novel autophagy inhibitory strategies to overcome chemotherapy resistance in multiple myeloma	Marilena Tauro
1:30-5 p.m.	Poster Hall / Section 22	Poster Session	655 / 28	Necroptosis promotes tumor growth through IL1-alpha release and recruitment of immunosuppressive myeloid cells	Kay Hänggi
1:30-5 p.m.	Poster Hall / Section 21	Poster Session	621 / 22	Aging dampens lymphoma-provoked phenotypic and epigenomic changes to the adaptive immune system	Rebecca S. Hesterberg
1:30-5 p.m.	Poster Hall / Section 23	Poster Session	678 / 18	Investigating the mechanisms involved in HMGB1-dependent DNA uptake and STING activation in dendritic cells	Daiana P. Celias
1:30-5 p.m.	Poster Hall / Section 11	Poster Session	309 / 11	ATM phosphorylation of NRF2 promotes DNA damage repair	Cheyenne A. Schneider
1:30-5 p.m.	Poster Hall / Section 10	Poster Session	276 / 9	Delineating the role of vesicular glutamate transporter SLC17A7 in osteosarcoma	Niveditha Nerlakanti
1:30-5 p.m.	Poster Hall / Section 27	Poster Session	744 / 12	Treatment inequities among patients diagnosed with Hodgkin's lymphoma with and without HIV (2018-2019): an analysis of the US National Cancer Database	Jessica Yasmine Islam
1:30-5 p.m.	Poster Hall / Section 27	Poster Session	745 / 13	Burden of potential HIV and cancer-related treatment drug-drug interactions: An analysis of SEER-Medicare	Jessica Yasmine Islam
1:30-5 p.m.	Poster Hall / Section 1	Poster Session	12-Dec	Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression	Janine M. DeBlasi
1:30-5 p.m.	Poster Hall / Section 5	Poster Session	124 / 5	Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response	Taylor M. Bursell
1:30-5 p.m.	Poster Hall / Section 5	Poster Session	132 / 13	The molecular basis of an evolutionary arms race between cancer cells and their host	Arig A. Ibrahim-Hashim
1:30-5 p.m.	Poster Hall / Section 5	Poster Session	139 / 20	Exploiting interactions between ploidy and host physiology	Noemi Andor
1:30-5 p.m.	Poster Hall / Section 3	Poster Session	61 /2	PRDM16 is key for promoting bone metastatic prostate cancer cell survival during entry into dormancy	Mostafa Nasr
1:30-5 p.m.	Poster Hall / Section 3	Poster Session	65 / 6	HIRA is a master regulator of the proliferation-to-dormancy switch in breast cancer	Stanislav Drapela
3-5 p.m.	Valencia BC	Minisymposium		Genetically Engineered Anticancer T Cells	Jose-Alejandro Guevara
3:52-4:07 p.m.	Room W304 A-D	Minisymposium	1159	BRAF- mediated PHGDH induction establishes a metabolic vulnerability in melanoma	Neel Jasani
4:07-4:22 p.m.	Room W311 A-D	Minisymposium	1192	Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomeningeal lymphoma	Mariam Lotfy Khaled
4:35-4:45 p.m.	Valencia A	Clinical Trial Minisymposium		Novel Clinical Trials for Hematological Malignancies	William Dalton

Monday, April 17

Time	Room	Type	Abstract No.	Abstract Title	Authors
9 a.m.-12:30 p.m.	Poster Hall / Section 44	Poster Session	2307 / 21	Targeted cell-free DNA methylation signature in metastatic castration-resistant prostate cancer	Jodie Wong
9 a.m.-12:30 p.m.	Poster Hall / Section 46	Poster Session	CT056 / 14	A multicenter, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate-receptor-alpha-targeting antibody-drug conjugate in patients with selected tumor types	Robert Wenham
9 a.m.-12:30 p.m.	Poster Hall / Section 46	Poster Session	CT063 / 21	A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)	Hyo S. Han
9 a.m.-12:30 p.m.	Poster Hall / Section 22	Poster Session	1767 / 1	Biodistribution of zoledronate and effects on gd PSCA-CAR T cells in a model of bone metastatic prostate cancer	Leticia Tordesillas
9 a.m.-12:30 p.m.	Poster Hall / Section 22	Poster Session	1770 / 4	CD28-Y218 phosphorylation in CAR-T cells is mediated by the IL-2-inducible T-cell kinase (ITK)	Elena Martinez-Planes
9 a.m.-12:30 p.m.	Poster Hall / Section 24	Poster Session	1840 /12	Methylmalonic acid accumulation suppresses CD8+ T cell activation and contributes to age-induced immunosuppression	Joanne D. Tejero
9 a.m.-12:30 p.m.	Poster Hall / Section 28	Poster Session	1974 / 15	Predictors of correct recall of MC1R genetic risk among Hispanic individuals participating in a skin cancer precision prevention trial	John C. A. Lacson
9 a.m.-12:30 p.m.	Poster Hall / Section 27	Poster Session	1956 / 30	Stress-mediated reactive oxygen species from mitochondria dysregulates the tumor microenvironment in prostate cancer of African American men	Asmaa El-Kenawi
9 a.m.-12:30 p.m.	Poster Hall / Section 26	Poster Session	1916 / 22	Cancer disparities among sexual and gender minority patients at a National Cancer Institute-Designated Comprehensive Cancer Center	Shahrzad A. Zamani
9 a.m.-12:30 p.m.	Poster Hall / Section 26	Poster Session	1896 / 2	Dysregulation of DNA methylation in prostate cancer among African American men	Jong Y. Park
9 a.m.-12:30 p.m.	Poster Hall / Section 33	Poster Session	2068 / 4	MCAP Explore: A self-service data exploration and cohort building tool for oncologists	Rachel Howard
9 a.m.-12:30 p.m.	Poster Hall / Section 33	Poster Session	2078 / 14	VALIS: Virtual Alignment of pathoLogy Image Series for multi-gigapixel whole slide images	Chandler Dean Gatenbee
9 a.m.-12:30 p.m.	Poster Hall / Section 33	Poster Session	2086 / 22	ISCVAM, an Interactive Single Cell Visual Analytics for Multiomics, accelerates the identification of novel rare cell populations	Thanh N. M. Nguyen
9 a.m.-12:30 p.m.	Poster Hall / Section 33	Poster Session	2089 / 25	Vanishing deviance problem in high-dimensional penalized Cox regression	Sijie Yao
9 a.m.-12:30 p.m.	Poster Hall / Section 40	Poster Session	2161	Quinolinic acid phosphoribosyl transferase (QPRT) is an essential liability of non-small cell lung cancer	Hossein Kashfi
12:35-12:55 p.m.	Tangerine Ballroom 2 (WF2)	Major Symposium		A structural blueprint for understanding LAG3 agonism and antagonism	Vince Luca
1:30-5 p.m.	Poster Hall / Section 33	Poster Session	3171 / 24	Detecting ploidy specific vulnerability to resource restriction: An integrated in vitro and in silico approach	Richard J. Beck
1:30-5 p.m.	Poster Hall / Section 31	Poster Session	3096 / 9	Development of pyrrolopyrimidine-based ACK1 inhibitors for cancer therapeutics	Angelie Matar
1:30-5 p.m.	Poster Hall / Section 31	Poster Session	3107 / 20	Development of novel JAK2 inhibitors and PROTACs as chemical probes for the investigation of JAK2 inhibition and degradation	Briley A. Humphrey
1:30-5 p.m.	Poster Hall / Section 37	Poster Session	3197 / 17	Adoptive T cell therapy using IL-7 and IL-15 expanded HER2-specific CD4 T cells for metastatic breast cancer	Namrata Gautam
1:30-5 p.m.	Poster Hall / Section 40	Poster Session	3264 / 5	Sotorasib, a selective G12C K-RAS inhibitor, modulates the tumor microenvironment to promote TNFα and IFNγ signaling and augment immunotherapy response	Mohammed L. Ibrahim
1:30-5 p.m.	Poster Hall / Section 45	Poster Session	CT103 / 11	A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity	Andreas N. Saltos
1:30-5 p.m.	Poster Hall / Section 47	Poster Session	CT157 / 19	Combination of nivolumab with standard of care in the management of grade group 5 prostate cancer: Interim analysis of a phase II trial	John Michael Bryant
1:30-5 p.m.	Poster Hall / Section 20	Poster Session	2856 / 14	Age-induced chronic accumulation of cortisol drives chemotherapy resistance in lung cancer	Devesh Raizada
1:30-5 p.m.	Poster Hall / Section 20	Poster Session	2858 / 16	Radiotherapy and NK cell-based immunotherapy: An evolutionary double-bind	Kimberly Luddy
1:30-5 p.m.	Poster Hall / Section 21	Poster Session	2881 / 19	Investigating cholesterol transfer between macrophages and prostate cancer cells	Olabisi Osunmakinde
1:30-5 p.m.	Poster Hall / Section 28	Poster Session	3049 / 21	Health-related quality of life among newly diagnosed young adult colorectal cancer patients: results from the ColoCare Study	Amanda Michelle Bloomer
1:30-5 p.m.	Poster Hall / Section 28	Poster Session	3055 / 27	Associations of the mucosal microbiome and circulating bile acids with colorectal adenoma among average-risk women	Maria F. Gomez
1:30-5 p.m.	Poster Hall / Section 27	Poster Session	3008 / 4	Association between distress and the tumor immune microenvironment in women with ovarian cancer	Cassandra A. Hathaway
1:30-5 p.m.	Poster Hall / Section 2	Poster Session	2391 / 13	Transdermal alkalinization treatment induces pH changes in a murine melanoma model as measured with MRI-CEST pH imaging	Pietro Irrera
3:07-3:22 p.m.	Valencia A	Minisymposium	3465	HDAC8 regulates immune escape in melanoma through increased transcription of inhibitory cytokines that increase accumulation of myeloid-derived suppressor cells (MDSCs)	Chao Zhang
5:44-6:06 p.m.	W315	Special Session		AACR-ASCO Joint Session: Myeloid-targeted Agents for Solid Tumors	Paulo C. Rodriguez

Tuesday, April 18

Time	Room	Type	Abstract No.	Abstract Title	Authors
9 a.m.-12:30 p.m.	Poster Hall / Section 34	Poster Session	LB175 / 8	Ploidy as a predictive biomarker for gemcitabine sensitivity in triple-negative breast cancers	Vural Tagal
9 a.m.-12:30 p.m.	Poster Hall / Section 33	Poster Session	4307 / 5	Integrative molecular subtypes of acute myeloid leukemia	Qianxing (Quincy) Mo
9 a.m.-12:30 p.m.	Poster Hall / Section 33	Poster Session	4313 / 11	A novel gene regulatory network model identifies master regulators in cancer	Praneeth Reddy Sudalagunta
9 a.m.-12:30 p.m.	Poster Hall / Section 14	Poster Session	3839 / 1	Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics	Yi Liao
9 a.m.-12:30 p.m.	Poster Hall / Section 38	Poster Session	4374 / 17	Patient provider communication about the use of medical cannabis for cancer symptoms	Kea Turner
9 a.m.-12:30 p.m.	Poster Hall / Section 41	Poster Session	4454 / 7	Loss of CX3CL1 expression mediates immune evasion in STK11 mutated lung adenocarcinomas	Gabriela M. Wright
9 a.m.-12:30 p.m.	Poster Hall / Section 19	Poster Session	3992 / 15	Elucidating reciprocal interactions between bone marrow stromal cells and a novel γδ CAR T cell therapy in the context of bone metastatic prostate cancer	Jeremy S. Frieling
9 a.m.-12:30 p.m.	Poster Hall / Section 22	Poster Session	4055 / 7	CD40L stimulates melanoma infiltrating B cells and enhances ex vivo TIL expansion	Renata Ariza Marques Rossetti
9 a.m.-12:30 p.m.	Poster Hall / Section 22	Poster Session	4056 / 8	Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma	Ganesan Ramamoorthi
9 a.m.-12:30 p.m.	Poster Hall / Section 9	Poster Session	3731 / 17	The polyamine-hypusine circuit controls an oncogenic translational program essential for malignant transformation in MYC-driven lymphoma	Shima Nakanishi
9 a.m.-12:30 p.m.	Poster Hall / Section 9	Poster Session	3739 / 25	MAFG promotes melanomagenesis through the transcriptional regulation of hypoxic and immune responses	Olga Vera
9 a.m.-12:30 p.m.	Poster Hall / Section 10	Poster Session	3743 / 1	circPMS1 is a pro-metastatic circular RNA in melanoma	Florian Karreth
9 a.m.-12:30 p.m.	Poster Hall / Section 4	Poster Session	3606 / 12	HDAC8-mediated inhibition of EP300 drives a neural crest-like transcriptional state that increases melanoma brain metastasis	Michael Emmons
10:15-11:45 a.m.	Room W315	Major Symposium		Project Site Selector: Navigating Oncology Drug Development through Troubled Waters	Jhanelle Gray
12:55-1:10 p.m.	Valencia BC	Major Symposium		A biobank of Fecal Immunochemical Tests (FIT) for gut microbiome measurement: A paradigm for studying the microbiome and cancer	Doratha Byrd
1:30-5 p.m.	Poster Hall / Section 39	Poster Session	5538 / 23	Prevalence of factors serving as common cancer clinical trial eligibility criteria by race and ethnicity	Yayi Zhao
1:30-5 p.m.	Poster Hall / Section 42	Poster Session	5612 / 3	Shape features of extra-nodal lesions on positron emission tomography identifies responders to CAR-T-cell therapy	Yoganand Balagurunathan
1:30-5 p.m.	Poster Hall / Section 22	Poster Session	5150 / 22	Improvement of hematopoiesis in primary low risk MDS with the TGFBR1 investigational inhibitor TP-6379	Erika A. Eksioglu
1:30-5 p.m.	Poster Hall / Section 23	Poster Session	5109 / 12	The anti-PD1+anti-LAG3 and anti-CTLA4+anti-PD1 combinations have non-overlapping mechanisms of action in melanoma cranial and extra cranial metastases	Manali S. Phadke
1:30-5 p.m.	Poster Hall / Section 10	Poster Session	4784 / 14	Multiomic landscape of evolution of Warburg effect identifies drivers of breast cancer	Rafael Renatino Canevarolo
1:30-5 p.m.	Poster Hall / Section 8	Poster Session	4722 / 7	Chronic upregulation of glucocorticoid hormones triggers chromatin remodeling in NSCLC through dynamic regulation of histone H3 chaperones	Benito M. Traversa
1:30-5 p.m.	Poster Hall / Section 12	Poster Session	4843 / 16	Characterization of T-cell metabolic defects in chronic lymphocytic leukemia preclinical model	Wael Gamal
1:30-5 p.m.	Poster Hall / Section 3	Poster Session	4586 / 4	To define how the uvel melanoma-liver environment crosstalk shapes metastasis growth and therapeutic response	Sathya Neelature Sriramareddy
2:30-4:30 p.m.	Valencia BC	Minisymposium		Clinical Applications of Artificial Intelligence and Mathematical Oncology	Heiko Enderling
2:30-4:30 p.m.	Room W414	Minisymposium		The Next Wave of Precision Oncology: New Drugs, Databases, and Analytics to Refine Care	Shelley Tworoger
2:30-4:30 p.m.	Room W307	Minisymposium		Survivorship and Biomarkers of Prognosis	Lauren Cole Peres
2:37-2:52 p.m.	Room W307	Minisymposium	5757	Breast cancer diagnosis and treatment associated with acceleration of biological aging over time in a racially diverse cohort of women	Jacob K. Kresovich
2:52-3:07 p.m.	Valencia BC	Minisymposium	5694	Adaptive treatment scheduling of PARP inhibitors in ovarian cancer: Using mathematical modeling to assess clinical feasibility and estimate potential benefits	Maximilian A. R. Strobl
3:07-3:22 p.m.	Valencia A	Minisymposium	5703	The immune cell state atlas analysis predicts therapeutic benefits with immune checkpoint inhibitors	Tingyi Li
3:22-3:37 p.m.	Valencia A	Minisymposium	5704	An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma	Ahmad A. Tarhini

Wednesday, April 19

Time	Room	Type	Abstract No.	Abstract Title	Authors
9 a.m.-12:30 p.m.	Poster Hall / Section 35	Poster Session	LB326 / 17	Combined inhibition of BRD4 and FAK1 as a novel therapeutic strategy for neurofibromatosis type 2 related schwannomas	Maria Alejandra Gonzalez
9 a.m.-12:30 p.m.	Poster Hall / Section 36	Poster Session	LB351 / 19	A novel mouse model to interrogate the functional relationship between protein synthesis and antigen presentation in cancer	Alex M. Jaeger
9 a.m.-12:30 p.m.	Poster Hall / Section 36	Poster Session	LB353 / 21	The switch from cap-dependent to cap-independent translation reshapes the immunopeptidome of lung cancer	Anika N. Ali
9 a.m.-12:30 p.m.	Poster Hall / Section 30	Poster Session	6549 / 15	Investigating the effects of density and frequency-dependent selection on subpopulations of cancer cells defined by copy number	Thomas A. Veith
9 a.m.-12:30 p.m.	Poster Hall / Section 32	Poster Session	6614 / 19	Spatial transcriptomic driven mechanistic model to investigate and predict pathogenesis of oligodendroglioma	Sandhya Prabhakaran
9 a.m.-12:30 p.m.	Poster Hall / Section 32	Poster Session	6625 / 30	Mathematical modeling of single-cell data reveals the key role of stochasticity - not fitness - in determining the clonal origins of relapse in childhood leukemia	Virginia Turati
9 a.m.-12:30 p.m.	Poster Hall / Section 38	Poster Session	6642 / 14	Rapid tissue donation identifies LAG3 as a potential therapeutic target for ALK fusion positive lung cancer	Hilal Ozakinci
9 a.m.-12:30 p.m.	Poster Hall / Section 24	Poster Session	6398 / 11	Targeting ENPP1 to boost anti-tumor immunity during PARP inhibition	Jie Li
9 a.m.-12:30 p.m.	Poster Hall / Section 24	Poster Session	6401 / 14	HMGB1 release predicts chemotherapy combinatorial efficacy with TIM-3 blockade	Alexis Onimus
9 a.m.-12:30 p.m.	Poster Hall / Section 25	Poster Session	6414 / 1	Concomitant anti-tumor immunity and checkpoint blockade responses are restored by depletion of CD62L expressing cells	Jose-Alejandro Guevara-Patino
9 a.m.-12:30 p.m.	Poster Hall / Section 12	Poster Session	6065 / 5	Patterns of dysregulated coding and noncoding gene expression in high-grade serous ovarian carcinomas	Brett M. Reid
9 a.m.-12:30 p.m.	Poster Hall / Section 11	Poster Session	6029 / 2	Multi-omic landscape of squamous cell lung cancer	Paul Stewart
9 a.m.-12:30 p.m.	Poster Hall / Section 27	Poster Session	6485 / 6	Oxidative phosphorylation-associated radiomic feature and survival of women with serous ovarian cancer	Christelle Colin-Leitzinger
10:15-11:45 a.m.	Room W312	Advances in Organ Site Research Session		The Role of Aging, Immunity, Microbiome, and Metabolism in Next Generation Melanoma Therapeutics	Patrick Hwu
10:20-10:40 a.m.	Room W311 A-D	Major Symposium		Integrating evolutionary dynamics into cancer therapy	Robert A. Gatenby

Moffitt Presentations at AACR 2023

Friday, April 14

Saturday, April 15

Sunday, April 16

Monday, April 17

Tuesday, April 18

Wednesday, April 19

Cambiar el idioma